SMYD2 and cancer: To validate and further investigate the mechanisms by which SMYD2 is implicated in cancer and other biological processes, 3-cyano-5-{2-[4-[2-(3-methylindol-1-yl)ethyl]piperazin-1-yl]-phenyl}-N-[(3-pyrrolidin-1-yl)propyl]benzamide (LLY-507), a potent cell-permeable and selective small molecule inhibitor of SMYD2, was developed.